Genitourinary cancers include those cancers affecting the male reproductive organs, as well as the urinary systems of both sexes. Texas Oncology puts its patients’ comfort at the forefront when treating cancers involving the bladder, kidney, prostate, and testes.
The Genitourinary Oncology program at Texas Oncology provides subspecialty oncology care for its patients, evaluating each individual on a case-by-case basis to determine the optimal method of treatment. Patients treated at participating Texas Oncology cancer treatment centers and clinics have access to comprehensive cancer treatment and care including the latest chemotherapy, radiation therapy and clinical trials.
The Genitourinary program is a member of several research consortiums and has been recognized as a leading participant in several clinical trials that resulted in FDA approval of important new cancer therapies. Texas Oncology also collaborates with other top-rated academic cancer centers and with The US Oncology Network to provide innovative and effective treatments available to its Genitourinary cancer patients.
Among the services provided:
- Access to research programs and clinical trials
- Weekly pathology reviews and tumor conferences
- Social work and clinical nutrition specialists
- On-site comprehensive laboratory and radiological facilities
As your Genitourinary oncologists, we work closely with your primary physicians to provide you with the best care possible from diagnosis through survivorship.
Genitourinary Oncology Information
Genitourinary cancer includes prostate, bladder, renal, and testicular cancer. The following facts provide some insight into these forms of cancer:
- Prostate cancer is the second-leading cause of cancer death in men after lung cancer. One man in six will get prostate cancer during his lifetime.
- Bladder cancer is four times more likely to be found in men than women. It is the fourth most frequent cancer diagnosed in men.
- Kidney cancer is among the 10 most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer is about 1 in 75 (1.34 percent); this risk is higher in men than in women.
- Testicular cancer is rare, but remains the most frequent cancer in males under 35 years of age*. It is one of the most curable forms of cancer, with a 99-percent survival rate if the cancer has not spread.
Treatment options for the various types of Genitourinary cancers vary. Chemotherapy, radiation therapy, and surgery may be considered depending upon the type of cancer, its stage, and other factors.
Sources: All material in this section comes from American Cancer Society, except as noted.
*– National Cancer Institute, “General Information About Testicular Cancer.”
As a Texas Oncology patient, you may have the opportunity to receive newly-developed treatments or experimental drugs through participation in research studies and clinical trials. These clinical trial programs are designed to evaluate new cancer prevention and treatment options, as part of a deliberate and comprehensive research process that often takes years. They test the safety and effectiveness of new or modified treatments in cancer patients using new drugs, unique approaches to surgery and radiation therapy, and various combinations of treatments. Participation in these trials is dependent on numerous factors relating to your health and the trials currently being offered.
Genitourinary Cancer Specialists